Home Newsfeeds Wedbush Maintains Outperform on Apple, Raises Price Target to $220

Wedbush Maintains Outperform on Apple, Raises Price Target to $220

Wedbush analyst Daniel Ives maintains Apple (NASDAQ:AAPL) with a Outperform and raises the price target from $200 to $220.

byBenzinga Newsdesk

August 17, 2022

1 minute read

Wedbush analyst Daniel Ives maintains Apple (NASDAQ:AAPL) with a Outperform and raises the price target from $200 to $220.

Larry Summers Says Fed Needs To Signal It’s Nearing End Of Rate Hikes: ‘Will Be Looking To See Whether…’

By Bhavik Nair

December 12, 9:32 PM

Former Treasury Secretary Lawrence H.

BND

Tourmaline Bio Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed

By Benzinga Newsdesk

January 24, 5:34 PM

Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory

TRML

News

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

By Happy Mohamed

August 4, 4:03 PM

IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, announced

CSE:IMCC

Moderna Strikes mRNA Drug Pact With Chinese Authorities: Report

By Vandana Singh

July 5, 1:06 PM

Moderna Inc (NASDAQ: MRNA) reportedly struck a deal with Chinese authorities to research, develop, and manufacture messenger RNA (mRNA) medicines in the country.

MRNA

Wedbush Maintains Outperform on Apple, Raises Price Target to $220

Related Posts

Larry Summers Says Fed Needs To Signal It’s Nearing End Of Rate Hikes: ‘Will Be Looking To See Whether…’

Tourmaline Bio Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Moderna Strikes mRNA Drug Pact With Chinese Authorities: Report